615 related articles for article (PubMed ID: 32671117)
41. Immunotherapy in managing metastatic melanoma: which treatment when?
Amaral T; Meraz-Torres F; Garbe C
Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339
[TBL] [Abstract][Full Text] [Related]
42. The role of targeted therapy for melanoma in the immunotherapy era.
Sullivan RJ
Semin Cutan Med Surg; 2018 Jun; 37(2):112-119. PubMed ID: 30040088
[TBL] [Abstract][Full Text] [Related]
43. [A decade of checkpoint inhibitors: current standard of care and future trends].
Reischer A; Kruger S; von Bergwelt-Baildon M
Dtsch Med Wochenschr; 2021 Sep; 146(17):1108-1118. PubMed ID: 34448187
[TBL] [Abstract][Full Text] [Related]
44. Immune checkpoint inhibitors in ocular melanomas: contrasting efficacy with cutaneous melanomas.
Hoyek S; Kourie HR; Labaki C; Antoun J
Immunotherapy; 2020 Nov; 12(16):1149-1152. PubMed ID: 33076742
[No Abstract] [Full Text] [Related]
45. Conjunctival Melanoma: Current Treatments and Future Options.
Grimes JM; Shah NV; Samie FH; Carvajal RD; Marr BP
Am J Clin Dermatol; 2020 Jun; 21(3):371-381. PubMed ID: 31965542
[TBL] [Abstract][Full Text] [Related]
46. Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges.
Millet A; Martin AR; Ronco C; Rocchi S; Benhida R
Med Res Rev; 2017 Jan; 37(1):98-148. PubMed ID: 27569556
[TBL] [Abstract][Full Text] [Related]
47. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.
Miller DM; Flaherty KT; Tsao H
Semin Cutan Med Surg; 2014 Jun; 33(2):60-7. PubMed ID: 25085663
[TBL] [Abstract][Full Text] [Related]
48. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
49. Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma-An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer.
Wahl RU; Leijs M; Araujo A; Rübben A
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32188047
[TBL] [Abstract][Full Text] [Related]
50. Principles of Immunotherapy in Melanoma.
Onitilo AA; Wittig JA
Surg Clin North Am; 2020 Feb; 100(1):161-173. PubMed ID: 31753110
[TBL] [Abstract][Full Text] [Related]
51. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
52. PET-guided Switch from Immunotherapy to Targeted Therapy in a Metastatic Melanoma Patient: a personalized approach.
Proietti I; Filippi L; Michelini S; Porta N; Bernardini N; Mambrin A; Tolino E; Pacini L; Rosa P; Calogero A; Romeo G; Di Cristofano C; Petrozza V; Bagni O; Skroza N; Potenza C
Clin Ter; 2020; 171(4):e283-e287. PubMed ID: 32614358
[TBL] [Abstract][Full Text] [Related]
53. [Immunotherapy for malignant melanoma].
Zaremba A; Zimmer L; Griewank KG; Ugurel S; Roesch A; Schadendorf D; Livingstone E
Internist (Berl); 2020 Jul; 61(7):669-675. PubMed ID: 32462249
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy and experimental approaches for metastatic melanoma.
Atkins MB
Hematol Oncol Clin North Am; 1998 Aug; 12(4):877-902, viii. PubMed ID: 9759585
[TBL] [Abstract][Full Text] [Related]
55. The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy.
Dong L; Tian X; Zhao Y; Tu H; Wong A; Yang Y
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499102
[TBL] [Abstract][Full Text] [Related]
56. Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.
Wood K; Luke JJ
Curr Oncol Rep; 2016 Nov; 18(11):67. PubMed ID: 27613168
[TBL] [Abstract][Full Text] [Related]
57. Blockade of CCR5 in melanoma: An alternative immune checkpoint modulator.
Escandon Brehm J; Bedogni B
Exp Dermatol; 2020 Feb; 29(2):196. PubMed ID: 31785018
[TBL] [Abstract][Full Text] [Related]
58. The Abscopal Effect in the Era of Checkpoint Inhibitors.
Kodet O; Němejcova K; Strnadová K; Havlínová A; Dundr P; Krajsová I; Štork J; Smetana K; Lacina L
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281259
[TBL] [Abstract][Full Text] [Related]
59. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape.
Levine O; Devji T; Xie F
Immunotherapy; 2017 Mar; 9(5):375-378. PubMed ID: 28357918
[No Abstract] [Full Text] [Related]
60. Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.
Sanlorenzo M; Vujic I; Moy A; Quaglino P; Fierro MT; Gammaitoni L; Carnevale-Schianca F; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2015; 15(10):1491-500. PubMed ID: 26206099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
